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Abstract 
 
Objective 
To investigate whether exposure to inhibitors of gastric acidity, such as H2 blockers or proton pump 
inhibitors, can independently increase the risk of infections in very low birth weight (VLBW) 
preterm infants in the neonatal intensive care unit. 
Study design 
This is a secondary analysis of prospectively collected data from a multicenter, randomized 
controlled trial of bovine lactoferrin (BLF) supplementation (with or without the probiotic 
Lactobacillus rhamnosus GG) vs placebo in prevention of late-onset sepsis (LOS) and necrotizing 
enterocolitis (NEC) in preterm infants. Inhibitors of gastric acidity were used at the recommended 
dosages/schedules based on the clinical judgment of attending physicians. The distribution of days 
of inhibitors of gastric acidity exposure between infants with and without LOS/NEC was assessed. 
The mutually adjusted effects of birth weight, gestational age, duration of inhibitors of gastric 
acidity treatment, and exposure to BLF were controlled through multivariable logistic regression. 
Interaction between inhibitors of gastric acidity and BLF was tested; the effects of any day of 
inhibitors of gastric acidity exposure were then computed for BLF-treated vs -untreated infants. 
Results 
Two hundred thirty-five of 743 infants underwent treatment with inhibitors of gastric acidity, and 
86 LOS episodes occurred. After multivariate analysis, exposure to inhibitors of gastric acidity 
remained significantly and independently associated with LOS (OR, 1.03; 95% CI, 1.008-1.067; P =
 .01); each day of inhibitors of gastric acidity exposure conferred an additional 3.7% odds of 
developing LOS. Risk was significant for Gram-negative (P < .001) and fungal (P = .001) pathogens, 
but not for Gram-positive pathogens (P = .97). On the test for interaction, 1 additional day of 
exposure to inhibitors of gastric acidity conferred an additional 7.7% risk for LOS (P = .003) in 
BLF-untreated infants, compared with 1.2% (P = .58) in BLF-treated infants. 
Conclusion 
Exposure to inhibitors of gastric acidity is significantly associated with the occurrence of LOS in 
preterm VLBW infants. Concomitant administration of BLF counteracts this selective disadvantage. 
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Introduction 
Despite increased awareness and adoption of prophylactic measures, infections in preterm very low 
birth weight (VLBW) neonates in the neonatal intensive care unit (NICU) are frequent and are 
associated with substantial short-and long-term morbidity, increased health costs, and poor 
neurosensorial and neurodevelopmental outcomes in survivors.1, 2, 3 Accordingly, strategies that 
aim to prevent rather than treat infections have been developed, and include hygiene measures, use 
of central venous catheter infection prevention practices, pharmacologic and nutritional prophylaxis, 
and medical stewardship.4, 5 
Despite the lack of class A evidence, inhibitors of gastric acid, such as H2 blockers (H2B; eg, 
ranitidine, cimetidine) and proton-pump inhibitors (PPIs; eg, omeprazole) have been widely used in 
recent decades in preterm infants to prevent upper gastrointestinal bleeding and to manage oral 
feeding intolerance or gastroesophageal reflux.6 
Gastric acidity is a primitive, innate defensive system that decreases the density of ingested 
microorganisms passed pathogens from the stomach to the gut, hence decreasing the burden of 
microorganisms in the gut, which can disseminate into the bloodstream via an immature and leaky 
gut barrier.7 Inhibitors of gastric acidity increase stomach pH, thereby decreasing the gastric acid 
barrier and potentially increasing the risk of systemic infection and necrotizing enterocolitis 
(NEC).8, 9, 10, 11, 12, 13 
An association between exposure to inhibitors of gastric acidity and NICU infections has been 
suggested in a limited number of studies using a retrospective cohort or prospective observational 
design.9, 13, 14, 15, 16 The current level of evidence has some weaknesses and limitations. An 
association has been assessed using only a dichotomous approach (ie, exposure to inhibitors of 
gastric acidity: yes vs no). Moreover, the magnitude of association is uncertain, and the hypothesis 
of an association between inhibitors of gastric acidity and neonatal infections has not been tested 
using a prospective, randomized clinical trial design. Finally, it is not known whether any 
interaction exists between inhibitors of gastric acidity and concomitant prophylaxis with anti-
infective medications. 
In this study, we aimed to test the hypothesis that exposure to inhibitors of gastric acidity 
independently increases the risk of infections in preterm VLBW neonates. A second aim of this 
study was to explore the possible benefits of bovine lactoferrin (BLF) in preterm VLBW infants 
exposed to inhibitors of gastric acidity. 
Methods 
This is a secondary analysis of data obtained during a multicenter randomized controlled trial 
(RCT) (isrctn.org: ISRCTN53107700) performed in Italy and New Zealand from 2006 to 2010. The 
original study protocol, including structured criteria for inclusion/exclusion, enrollment, 
randomization, ethics, and institutional approvals, has been published previously.17, 18 In short, 
preterm VLBW neonates from 11 tertiary NICUs were enrolled before 72 hours of life and were 
randomly assigned to receive BLF alone (LF100; Dicofarm, Rome, Italy; 100 mg/day and 372 mg of 
fructo-oligosaccharides [FOS] per packet; group A1) or in combination with the probiotic 
Lactobacillus rhamnosus GG (LGG) (Dicoflor60; Dicofarm; 106 colony-forming units per day; 
group A2) or placebo (group B) from birth to day of life 30 (day of life 45 for those weighing 
<1000 g at birth). The drugs and placebo were administered orally, once daily. Neonates not feeding 
in the first 48 hours received the drug(s)/placebo by orogastric tube. The results from this RCT 
showed that BLF supplementation, either alone or in combination with LGG, reduces the risk of 
late-onset sepsis18 and NEC17 in VLBW infants compared with placebo. 
In accordance with protocol, clinical and management data were collected prospectively for all 
enrolled infants until death or discharge. Systematic clinical surveillance for adverse events was 
performed through daily infant examination until 2 days after the end of treatment. Nutritional and 
feeding policies were stable during the study and consistent across centers, following common 
guidelines19 and adherence to the study protocol.18 Clinical surveillance for detection of sepsis was 
performed in all enrolled infants, with complete laboratory and microbiology evaluation in cases of 
suspected LOS. 
In this secondary analysis, information regarding physicians' discretionary use, dosages, dosing 
schedules, and days of treatment of inhibitors of gastric acidity, as well as potential risk factors for 
infection, were reviewed from the study dataset, together with all data regarding fungal colonization 
and episodes of LOS. 
The primary endpoint was the effect and magnitude of effect of inhibitors of gastric acidity 
exposure on the incidence of infections. We focused on the first episodes of LOS. Additional 
endpoints were to assess the effect of inhibitors of gastric acidity administration on fungal 
colonization and on NEC, the specific pathogens involved in the putative increased risk for sepsis 
attributable to inhibitors of gastric acidity, and whether oral supplementation of BLF (with or 
without the probiotic LGG) affects the occurrence of LOS and/or NEC in preterm VLBW neonates 
exposed to inhibitors of gastric acidity. 
Inhibitors of gastric acidity were prescribed following common protocols and based on the clinical 
judgment of attending physicians, mainly for prevention of upper gastrointestinal bleeding (during 
medical treatment of patent ductus arteriosus) and management of oral feeding intolerance or 
gastroesophageal reflux in the enrolled infants. Dosages and schedules were the same for all 
participating centers, and followed current guidelines and recommendations. Ranitidine was 
administered at 0.5 mg/kg every 12 hours intravenously or 1-2 mg/kg every 8 hours orally. 
Cimetidine was administered at 2.5-5 mg/kg every 8-12 hours intravenously or orally. Omeprazole 
was dosed at 2-3 mg/kg/day. LOS was defined as an episode of infection occurring >72 hours after 
birth and before discharge, detected by clinical signs and symptoms, laboratory findings consistent 
with sepsis, and isolation of a causative organism from blood (drawn from peripheral sites), urine 
(collected by suprapubic puncture or bladder catheterization, with growth of >100 000 colony-
forming units/mL [>10 000 for fungi]), or cerebrospinal or peritoneal fluid. Diagnostic criteria were 
based on the existing literature and guidelines from international consensus documents.17, 20, 21, 
22, 23 
Presumed sepsis (ie, clinical presentation consistent with sepsis without isolation of a 
microorganism) was not considered LOS, and thus was not analyzed in this study. 
Systematic surveillance for detection of fungal colonization was performed through clinical and 
weekly surveillance cultures (at least 3 cultures per week from different peripheral sites) during the 
study period. Fungal colonization was defined as the detection of at least 1 surveillance culture 
positive for fungi during the NICU stay. 
Standard laboratory methods were used to identify bacteria from cultures.24, 25 For Candida 
species, specimens were incubated on chromogen culture plates (Albicans ID; bioMérieux, Marcy 
l'Etoile, France) to identify Candida albicans blue-staining colonies after 48 hours of incubation at 
37 °C. Colonies were speciated biochemically (Vitec Yeast; bioMérieux). 
NEC was defined as Bell stage ≥2, that is, clinical signs with the presence of pneumatosis 
intestinalis on abdominal radiographs.26 
The criteria for hospital discharge were weight ≥1800 g, full oral feeding, and resolution of acute 
medical conditions. 
Episodes of sepsis were treated with antibiotics/antifungal agents in accordance with the literature,27 
guidelines from international consensus documents, and recommendations of the Italian 
Neonatology Society's Fungal Infections Task Force.22 Blinding was not broken to guide therapy. 
Statistical Analyses 
The association between exposure to inhibitors of gastric acidity (on any single day) and LOS was 
analyzed for all enrolled infants, and then separately for treatment groups (BLF/BLF+LGG vs 
placebo). All primary and secondary outcomes were analyzed on an intention-to-treat basis. 
The variables analyzed were rates of LOS, invasive fungal infection, fungal colonization, NEC, and 
all-cause death before discharge. Groups A1 and A2 were compared separately to group B. 
Proportions and continuous variables were compared using the Fisher exact 2-tailed test and 
Student t test, respectively. The Wilcoxon Mann-Whitney test was used to compare the distribution 
of days of inhibitors of gastric acidity treatment between those with and without the outcome. 
Multivariable logistic regression was used to assess the mutually adjusted effects of variables 
significantly associated with LOS in univariate analysis: birth weight, gestational age, days of 
gastric acidity inhibitor treatment, exposure to BLF, and exposure to BLF+LGG. The interaction 
between inhibitors of gastric acidity and BLF was tested, and the effect of 1 extra day of treatment 
with inhibitors of gastric acidity was then computed for neonates treated with BLF and those not 
treated with BLF. Risk ratios (RRs) and 95% CIs were calculated to compare cumulative between-
group incidences using Stata 13 (StataCorp, College Station, Texas). All tests were 2-tailed, and P <
 .05 was considered to indicate statistical significance. All computations were performed using 
SPSS for Windows, version 16.0 (SPSS, Chicago, Illinois). 
Results 
A total of 743 VLBW neonates (247 in group A1, 238 in group A2, and 258 in group B) were 
enrolled and analyzed in the original trial.18 Of these, 235 infants were treated with inhibitors of 
gastric acidity for at least 1 day and thus were eligible for this secondary analysis. 
Demographics and clinical characteristics were similar in the 3 groups (Table I). The proportion of 
infants exposed to inhibitors of gastric acidity treatment, as well as the mean duration of the 
exposure to inhibitors of gastric acidity, were similar in all groups. The proportion of infants treated 
with inhibitors of gastric acidity was 31.1% in group A1 (77 of 247), 30.6% in group A2 (73 of 
238), and 33.0% in group B (85 of 258) (P = .99 for both comparisons). Among the infants, PPIs 
were used in 4 of 77 in group A1, in 5 of 73 in group A2, and in 6 of 85 in groups B. Only 1 patient 
(in group B) received combined treatment with both classes of inhibitors of gastric acidity (H2B 
plus PPIs). The mean duration of inhibitors of gastric acidity treatment was 2.8 days in group A1, 
3.2 days in group A2, and 3.3 days in group B (P = .55 and 0.99, respectively). 
Table I. Demographic, clinical, and nutritional characteristics of the patients enrolled 
Characteristics Group A1 Group A2 Group B P value
Number of patients (total, 743) 247 238 258  
Birth weight, g, mean ± SD, range 1158 ± 251,605-1495 
1129 ± 242,
550-1500 
1118 ± 259,
437-1500 NS 
Gestational age, wk, mean ± SD, range 29.7 ± 2.5,23-36 
29.6 ± 2.8,
23-35 
29.4 ± 3.1,
23-39 NS 
Characteristics Group A1 Group A2 Group B P value
Apgar score at 5 min, mean ± SD 7.4 ± 1.4 7.4 ± 1.7 7.5 ± 1.6 NS 
Use of TPN, d, mean ± SD 19.1 ± 20.1 17.7 ± 18.9 18.0 ± 17.0 NS 
Intubation, d, mean ± SD 5.3 ± 5.3 4.8 ± 6.0 4.9 ± 9.2 NS 
Use of antibiotics, d, mean ± SD 11.6 ± 8.9 11.7 ± 9.2 13.1 ± 10.0 NS 
Use of postnatal early steroids, d, mean ± SD 0.7 ± 0.8 0.5 ± 1.0 0.9 ± 1.1 NS 
Central venous catheter, d, mean ± SD 13.5 ± 10.5 13.4 ± 10.4 14.8 ± 11.8 NS 
Mean stay in NICU, alive infants, d, mean ± SD 53.5 ± 24.4 53.7 ± 22.3 51.7 ± 21.7 NS 
Inhibitors of gastric acidity use, n 77 73 85 NS 
Duration of inhibitors of gastric acidity, d, mean ± SD 2.8 ± 6.1 3.2 ± 7.3 3.3 ± 7.5 NS 
LOS per inhibitors of gastric acidity patients in each group, n 10 8 22 NS 
Time of initiation of oral feeding, DOL, mean ± SD 2.0 ± 2.9 2.0 ± 3.4 2.2 ± 3.4 NS 
Time of achievement of full feeding, DOL, mean ± SD 12.3 ± 4.3 13.2 ± 5.0 14.6 ± 4.9 NS 
Volume of feedings advanced daily, mL/d, mean ± SD 10.3 ± 4.7 11.2 ± 3.8 11.0 ± 3.5 NS 
Infants fed with only formula milk, % 18.7 19.0 16.1 NS 
Infants fed with only fresh human milk, % 27.7 27.1 29.0 NS 
Infants fed with both formula and fresh human milk, % 53.4 51.8 49.0 NS 
Daily fresh human milk intake, mL/kg, mean ± SD 67.8 ± 42.9 64.1 ± 43.5 61.9 ± 40.0 NS 
Total duration of fresh human milk feeding, d, mean ± SD 21.7 ± 13.7 21.1 ± 14.1 21.8 ± 13.7 NS 
DOL, day of life; NS, not significant; TPN, total parenteral nutrition. 
Eighty-six first episodes of microbiologically confirmed LOS were diagnosed in the 743 VLBW 
infants enrolled. A total of 40 episodes of LOS occurred in the patients treated with inhibitors of 
gastric acidity (10 in group A1, 8 in group A2, and 22 in group B). The rates of LOS in these 
infants were 13% in group A1, 10.9% in A2, and 25.8% in B. After controlling for all variables 
significantly associated with infections, exposure to inhibitors of gastric acidity retained a 
significant and independent association with LOS (OR, 1.03; 95% CI, 1.008-1.067; P = .01) (Table 
II). Each additional day of therapy with inhibitors of gastric acidity conferred an additional 3.7% 
odds of developing develop infection. 
Table II. Associations of outcomes of interest and exposure to inhibitors of gastric acidity 
Outcomes 
Mean exposure to inhibitors of gastric 
acidity in infants with the specific 
outcome, d 
Mean exposure to inhibitors of gastric 
acidity in infants without the specific 
outcome, d 
OR 95 CI P value
Late-onset sepsis 
(microbiologically proven 
infection) 
4.67 2.49 1.035 1.008-1.064 .014 
Gram-positive infection 2.60 2.75 0.985 0.925-1.055 .69 
Gram-negative infection 5.83 2.44 1.046 1.019-1.074 .01 
Fungal infection 7.75 2.56 1.063 1.025-1.102 .01 
Fungal colonization 5.48 2.27 1.045 1.021-1.070 .001 
Death before discharge 1.90 2.77 0.947 0.872-1.029 .19 
Threshold ROP 5.74 2.53 1.042 1.012-1.073 .006 
NEC (Bell stage ≥2) 4.01 2.79 1.023 0.966-1.083 .044 
ROP, retinopathy of prematurity. 
Inhibitors of gastric acidity exposure was significantly associated with infection from Gram-
negative (P < .001) and fungal (P = .001) pathogens, but not from Gram-positive organisms (P = .97). 
A significant association was observed for enteric fungal colonization as well (P < .001). 
When analyzing the risk for infection in inhibitors of gastric acidity-treated infants according to 
BLF exposure (any type; test for interaction between BLF and inhibitors of gastric acidity), it was 
noted that each day of exposure to inhibitors of gastric acidity conferred an additional 7.7% risk for 
infection in infants not exposed to BLF (P = .003), compared with 1.2% (P = .58) in those receiving 
BLF (with or without LGG) (Table III). 
Table III. Test for interaction between BLF and inhibitors of gastric acidity 
Outcome Test for interaction OR P value 95% CI 
Interaction (BLF and inhibitors of gastric acidity) 0.939 .056 0.881-1.002 
Effect of 1 more d of inhibitors of gastric acidity in non–BLF-treated infants 1.077 .003 1.026-1.131 Infection 
Effect of 1 more d of inhibitors of gastric acidity in BLF-treated infants 1.012 .585 0.970-1.055 
Interaction (BLF and inhibitors of gastric acidity) 0.937 .019 0.888-0.989 
Effect of 1 more d of inhibitors of gastric acidity in non–BLF-treated infants 1.098 .000 1.047-1.151 Fungal colonization 
Effect of 1 more d of inhibitors of gastric acidity in BLF-treated infants 1.029 .035 1.002-1.057 
Interaction (BLF and inhibitors of gastric acidity) 0.816 .043 0.670-0.994 
Effect of 1 more d of inhibitors of gastric acidity in non–BLF-treated infants 1.214 .021 1.030-1.431 NEC (≥2nd stage) 
Effect of 1 more d of inhibitors of gastric acidity in BLF-treated infants 0.991 .866 0.886-1.107 
Note: This test was performed on all patients receiving BLF, regardless of concomitant 
administration of the probiotic LGG, because an additive effect of this last compound on the 
incidence of LOS was not demonstrated. 
A similar pattern was found for the relationships with fungal colonization and NEC (Table III). 
Importantly, 1 additional day of exposure to inhibitors of gastric acidity conferred an additional 
11.4% risk of NEC among infants not treated with BLF, whereas this risk decreased to 0 for BLF-
treated infants. 
No adverse effects or treatment intolerance occurred related to BLF administration. 
Discussion 
This study provides prospectively generated evidence that VLBW infants exposed to inhibitors of 
gastric acidity have significantly increased odds of developing infections, and that the risk increases 
with each day of exposure to inhibitors of gastric acidity. Our data also reveal that BLF or 
BLF+LGG exposure counteracts the risk for infections related to inhibitors of gastric acidity. In this 
study, the main pathogens causing infections in infants exposed to inhibitors of gastric acidity were 
Gram-negative bacilli and Candida spp. In addition, exposure to inhibitors of gastric acidity 
increased the risk of Candida spp colonization in the gut. The main reservoir of these 2 groups of 
microorganisms is the gut, unlike for many Gram-positive organisms. Our findings of increased 
LOS due to these 2 classes of pathogens are consistent with advantage provided by an impaired acid 
barrier. This is also in line with reports suggesting that Escherichia coli, Klebsiella pneumonia, and 
Pseudomonas aeruginosa are the main pathogens isolated in infants exposed to inhibitors of gastric 
acidity.15Candida colonization is the most potent risk factor for Candida systemic infection and the 
enteric reservoir is the main source for systemic dissemination in immunologically compromised 
patients such as preterm infants. A relevant body of evidence supports the use of fluconazole to 
prevent Candida colonization and infections in preterm infants.28, 29, 30, 31 In our previously 
reported results of a multicenter RCT of fluconazole prophylaxis in preterm infants, fluconazole 
was 70% effective in preventing Candida colonization.31 The present study shows that each day of 
exposure to inhibitors of gastric acidity confers a 4.5% additional risk of acquiring Candida 
colonization in preterm infants, and that concomitant administration of BLF (alone or with LGG) 
significantly reduces this risk. Strategies aimed at preventing Candida colonization and infection 
should consider withdrawal of inhibitors of gastric acidity to avoid Candida colonization, and 
studies should be conducted to verify whether fluconazole-based prophylactic strategies are 
hampered by the concomitant use of inhibitors of gastric acidity. 
The progressive time-related increase in the risk of infection, whether bacterial or fungal, 
determined by exposure to inhibitors of gastric acidity suggests that it may be worth investigating 
whether the duration and/or dosage of inhibitors of gastric acidity treatment in VLBW neonates 
should be reduced progressively after day 1. On the other hand, the similar decrease in risk of 
infection determined by BLF irrespective of duration of inhibitors of gastric acidity treatment 
suggests that such a strategy might not be necessary, providing that BLF treatment accompanies 
inhibitors of gastric acidity treatment. All the same, inhibitors of gastric acidity treatment may 
reduce an otherwise greater beneficial effect of BLF treatment on reduction of infection. A recent 
Cochrane Review reports that BLF reduces the frequency of infections in VLBW neonates in the 
NICU by 51%.32 The fact that BLF almost entirely counteracts the disadvantage of inhibitors of 
gastric acidity but does not further decrease the risk of infection to the level of neonates treated with 
BLF who are not exposed to inhibitors of gastric acidity suggest that the beneficial effect of BLF is 
somewhat mitigated by the detrimental effect of inhibitors of gastric acidity. 
Our data confirm, strengthen, and expand on previous reports describing an association between 
inhibitors of gastric acidity use and infections9, 13, 14, 15, 16 through its prospective and 
international multicenter design. In addition, the overall magnitude of the association and its 
specificity by pathogens was examined with variables related to local clinical practice were 
bypassed. Terrin et al15 assessed the risk of infection comparing infants exposed to ranitidine vs 
unexposed, but considered as exposed only those infants receiving at least 7 days of treatment. In 
the present era, most infants in the NICU are treated with inhibitors of gastric acidity only in 
specific circumstances, and only for a few days. 
Our study also shows that exposure to inhibitors of gastric acidity is independently associated with 
the occurrence of NEC, and that concomitant treatment with BLF mitigates this risk significantly. 
The results of our study expand some previously published evidence.15, 18 Because in our study, 
exposure to fresh human milk was comparable in the 3 groups, we excluded that the increased risk 
of developing NEC or LOS in infants exposed to inhibitors of gastric acidity was due to differences 
in exposure to nutrients that are known to affect the occurrence of infections and NEC. 
BLF reduces the rate of progression from enteric colonization with Candida spp to systemic 
infection.33 At high concentrations, BLF enhances maturation of the gut barrier by increasing the 
number of gut cells, promoting the closure of enteric gap junctions, thus reducing intestinal 
permeability and dissemination of gut organisms into the bloodstream.34, 35, 36, 37 This 
explanation is in line with the similar beneficial effect of BLF on bacterial33 and fungal causes of 
infection.38 In addition, BLF is also bifidogenic,39 thus contributing to the establishment of an 
advantageous microflora in the gut. We speculate that BLF's protective role in infants exposed to 
inhibitors of gastric acidity is a dual one. Furthermore, BLF has well-known antioxidative actions 
through reduction of free radicals of oxygen in the gut,40, 41 which might play a key role in this 
context. 
In the present study, the BLF product contained some amounts of FOS. Because FOS have actions 
similar to prebiotics or human oligosaccharides, we cannot exclude that the FOS contained in the 
BLF product might have affected the microbiome and ultimately contributed to the reported 
modifications in the pathogens' gut ecology in addition to the effect of lactoferrin. 
A limitation of this study is that the results are derived from a post hoc analysis of data from an 
RCT with a different primary outcome assessed. It is difficult to plan an RCT of inhibitors of gastric 
acidity use. Further investigation of the pathogenesis of infections in infants exposed to inhibitors of 
gastric acidity is warranted. Possibly, increased information on the mechanisms of gut colonization 
and on the development of enteric inflammation in such infants will provide a better understanding 
of the role of preventive strategies and the extent of the protective effect of BLF. Meanwhile, 
because even 1 day of exposure to inhibitors of gastric acidity confers additional, quantifiable risk 
of LOS, it seems prudent that inhibitors of gastric acidity be administered when only strictly 
necessary, over the shortest possible course, and with consideration of concomitant administration 
of BLF in an attempt to counteract adverse effects associated with the use of inhibitors of gastric 
acidity. 
Appendix 
Additional members of the Italian Task Force for the Study and Prevention of Neonatal Fungal 
Infections, affiliated with the Italian Society of Neonatology, includes the following institutions and 
individuals: 
• NICU, IRCCS S Matteo, Pavia: Amelia Di Comite, MD, Alessandro Borghesi, MD, Chryssoula 
Tzialla, MD 
• NICU, S Anna Hospital, Torino: Giovanni Agriesti, MD, Riccardo Arisio, MD, Caterina Franco, 
MD, Roberta Guardione, RN, Elena Boano, RN, Alessia Catarinella, RN, Cristina Romano, RN, 
Cesare Monetti, MD, Ugo Sala, MD, Caterina Carbonara, MD, Emmanuele Mastretta, MD, Paola 
Del Sordo, MD, Claudio Priolo, MD, Paolo Galletto, MD, Francesca Campagnoli, MD, Mauro 
Vivalda, MD, Giuseppina Bonfante, MD, Giovanna Gomirato, MD, Davide Montin, MD, Roberta 
Camilla, MD, Alessandro Messina, MD, Marta Pieretto, MD 
• NICU, University of Palermo: Domenico Cipolla, MD, Mario Giuffrè, MD, Giovanni Corsello, 
MD, PhD 
• NICU, La Sapienza University, Rome: Fabio Natale, MD 
• NICU, Fatebenefratelli Hospital, Benevento: Gennaro Vetrano, MD 
• NICU, University of Bologna: Elisabetta Tridapalli, MD, Giacomo Faldella, MD, PhD, Maria 
Grazia Capretti, MD 
• Neonatology Policlinico Casilino, Rome: PierMichele Paolillo, MD, Simonetta Picone, MD, 
Serafina Lacerenza, MD 
• NICU, Arcispedale Reggio Emilia: Giancarlo Gargano, MD, Cristiana Magnani, MD 
• NICU, Cà Foncello Hospital, Treviso: Onofrio Sergio Saia, MD 
• NICU, University of Modena: Elena Della Casa, MD 
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